Drug insight: Maintenance immunosuppression in kidney transplant recipients

Nature Clinical Practice Nephrology

Volumn 2, Issue 12, 2006, Pages 688-699

  Samaniego, Millie ^a   Becker, Bryan N ^a   Djamali, Arjang ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Calcineurin inhibitors; Immunosuppression; Kidney transplantation; Mycophenolate; Sirolimus

Indexed keywords

AZASAN; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LEFLUNOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TSUKUBAENOLIDE; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE;

ACIDURIA; ACNE; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADRENAL INSUFFICIENCY; AFRICAN AMERICAN; ANEMIA; ANTIGEN SPECIFICITY; BLOOD PRESSURE REGULATION; BONE DISEASE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONGENITAL MALFORMATION; CONVALESCENCE; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; ESOPHAGITIS; FETUS DEATH; GASTRITIS; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GOUT; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH CARE DELIVERY; HEPATITIS; HIGH RISK POPULATION; HIRSUTISM; HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; INTRAUTERINE GROWTH RETARDATION; INTROSPECTION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ACIDOSIS; LEUKOCYTOSIS; LIVER TOXICITY; LYMPHOCELE; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MOUTH PAIN; MYOPATHY; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PATIENT SAFETY; PEPTIC ULCER; POLYCYTHEMIA; PREGNANCY; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; PSYCHOSIS; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN DEFECT; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; VIRUS INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 33845245882     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0343     Document Type: Review

References (99)

1. Wolfe RA et al. (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725-1730
2. Sayegh MH and Carpenter CB (2004) Transplantation 50 years later - progress, challenges, and promises. N Engl J Med 351: 2761-2766
3. Kaplan B and Meier-Kriesche HU (2004) Renal transplantation: a half century of success and the long road ahead. J Am Soc Nephrol 15: 3270-3271
4. Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729
5. Meier-Kriesche HU et al. (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378-383
6. Meier-Kriesche HU et al. (2004) Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4: 1289-1295
7. Keith DS et al. (2005) Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 16: 1512-1521
8. Meyers CM and Kirk AD (2005) Workshop on late renal allograft dysfunction. Am J Transplant 5: 1600-1605
9. Halloran PF et al. (1999) Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 10: 167-181
10. Meier-Kriesche HU et al. (2003) Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75: 1291-1295
11. Kaplan B and Meier-Kriesche HU (2002) Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2: 970-974
12. [No authors listed] (2005) USRDS 2004 annual data report. Am J Kidney Dis 45 (Suppl 1): 8-280
13. Djamali A et al. (2006) Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol 1: 623-640
14. Djamali A et al. (2003) Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int 64: 1800-1807
15. Srinivas TR et al. (2005) Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 5: 207-217
16. Hirsch HH et al. (2005) Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79: 1277-1286
17. Meier-Kriesche HU et al. (2006) Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 6: 1111-1131
18. Shapiro R et al. (2005) Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 5: 874-886
19. Denton MD et al. (1999) Immunosuppressive strategies in transplantation. Lancet 353: 1083-1091
20. Lemahieu WP et al. (2004) CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 4: 1514-1522
21. Kasiske BL et al. (2000) Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11 (Suppl 15):S1-S86
22. Neylan JF (1998) Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 65: 515-523
23. Hardinger KL et al. (2004) Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 24: 1159-1176
24. Kapturczak MH et al. (2004) Pharmacology of calcineurin antagonists. Transplant Proc 36: 25S-32S
25. Pirsch JD et al. (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-983
26. Mayer AD et al. (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64: 436-443
27. Burdmann EA et al. (2003) Cyclosporine nephrotoxicity. Semin Nephrol 23: 465-476
28. Pham PT et al. (2000) Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 36: 844-850
29. Bennett WM et al. (1996) Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 50: 1089-1100
30. Gonwa T et al. (2003) Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclos porine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 75: 2048-2053
31. Meier-Kriesche HU and Kaplan B (2002) Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am J Transplant 2: 100-104
32. Holzmacher R et al. (2005) Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 20: 1456-1462
33. Tran HT et al. (2000) Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11: 1903-1909
34. Flechner SM et al. (2004) De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4: 1776-1785
35. Knechtle SJ et al. (2003) Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3: 722-730
36. Kreis H et al. (2004) Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809-817
37. Mota A et al. (2004) Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4: 953-961
38. Diekmann F et al. (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4: 1869-1875
39. Weir MR et al. (2001) Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59: 1567-1573
40. Kasiske BL et al. (2000) A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917
41. Mulay AV et al. (2005) Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 5: 1748-1756
42. Johnson RW et al. (2001) Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72: 777-786
43. Weir MR et al. (1997) A novel approach to the treatment of chronic allograft nephropathy. Transplantation 64: 1706-1710
44. Pilmore HL and Dittmer ID (2002) Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 16: 191-195
45. Weir MR et al. (2004) Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 24: 379-386
46. Parrish JA (2005) Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 353: 2712-2713
47. Buell JF et al. (2005) Malignancy after transplantation. Transplantation 80: S254-S264
48. O'Donovan P et al. (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309: 1871-1874
49. Halloran P et al. (1997) Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63: 39-47
50. Remuzzi G et al. (2004) Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 364: 503-512
51. Budde K et al. (2004) Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4: 237-243
52. Salvadori M et al. (2004) Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4: 231-236
53. Meier-Kriesche HU et al. (2005) Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. Am J Transplant 5: 1164-1166
54. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60: 225-232
55. [No authors listed] (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 345: 1321-1325
56. Srinivas TR et al. (2003) Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 4: 2325-2345
57. Meier-Kriesche HU et al. (2003) Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 3: 68-73
58. Shaw LM et al. (2003) Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3: 534-542
59. Borrows R et al. (2006) Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 6: 121-128
60. van Gelder T and Shaw LM (2005) The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80: S244-S253
61. Mladenovic V et al. (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 38: 1595-1603
62. van Roon EN et al. (2004) Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 27: 345-352
63. Hardinger KL et al. (2002) Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2: 867-871
64. Williams JW et al. (2005) Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 352: 1157-1158
65. Josephson MA et al. (2006) Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 81: 704-710
66. John GT et al. (2004) Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 77: 1460-1461
67. Saunders RN et al. (2001) Rapamycin in transplantation: a review of the evidence. Kidney Int 59: 3-16
68. Cattaneo D et al. (2004) Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 4: 1345-1351
69. Pascual J et al. (2005) Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation 79: S80-S84
70. Kirchner GI et al. (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43: 83-95
71. Kahan BD (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356: 194-202
72. MacDonald AS (2001) A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71: 271-280
73. Groth CG et al. (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-1042
74. Kreis H et al. (2000) Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260
75. Oberbauer R et al. (2003) Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76: 364-370
76. Lo A et al. (2004) Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 77: 1228-1235
77. Webster AC et al. (2006) Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81: 1234-1248
78. Meier-Kriesche HU et al. (2005) Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 5: 2273-2280
79. Meier-Kriesche HU et al. (2004) Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 4: 2058-2066
80. Senior PA et al. (2005) Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5: 2318-2323
81. van den Akker JM et al. (2006) Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 70: 1355-1357
82. Stephany BR et al. (2006) Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 82: 368-374
83. Knight RJ and Kahan BD (2006) The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? Kidney Int 70: 994-999
84. Brattstrom C et al. (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65: 1272-1274
85. Augustine JJ et al. (2004) Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 4: 2001-2006
86. McTaggart RA et al. (2004) Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 78: 475-480
87. Fritsche L et al. (2004) Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 4: 130-131
88. Franchimont D (2004) Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 1024: 124-137
89. Czock D et al. (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44: 61-98
90. Opelz G et al. (2005) Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5: 720-728
91. Hricik DE (2005) Steroid withdrawal for the (selected) masses. Am J Transplant 5: 639-640
92. Woodle ES et al. (2005) A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 5: 157-166
93. Vanrenterghem Y et al. (2005) Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 5: 87-95
94. Pascual J et al. (2004) Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 78: 1548-1556
95. Khwaja K et al. (2004) Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 4: 980-987
96. Hricik DE et al. (2003) Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 76: 938-942
97. Armenti VT et al. (2004) Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl [no issue listed] 103-114
98. Rahamimov R et al. (2006) Pregnancy in renal transplant recipients: long-term effect on patient and graft survival. A single-center experience. Transplantation 81: 660-664
99. Ostensen M et al. (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8: 209